Loading financial data...

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Financial Statements | Global Financial Data

Corbus Pharmaceuticals Holdings, Inc.

CRBPSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1595097

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	$881.7K	$3.9M
Research and Development Expense	$32.2M	$31.2M	$16.1M	$36.4M	$98.3M
Operating Expenses	$48.7M	$45.1M	$39.8M	$56.9M	$126.7M
Operating Income (Loss)	-$48.7M	-$45.1M	-$39.8M	-$56.0M	-$122.8M
Interest Expense	—	—	—	—	—
Nonoperating Income (Expense)	$8.5M	$474.0K	-$2.5M	$10.3M	$11.5M
Income Tax Expense (Benefit)	$0.00	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$155.9M	$28.3M	$66.3M	$107.7M	$102.3M
Assets, Current	$153.0M	$23.5M	$60.2M	$100.2M	$92.1M
Cash and Cash Equivalents, at Carrying Value	$17.2M	$13.7M	$17.0M	$25.0M	$85.4M
Liabilities	$13.5M	$35.2M	$33.3M	$38.6M	$57.0M
Liabilities, Current	$11.8M	$31.9M	$12.6M	$17.0M	$31.9M
Long-term Debt	—	—	$17.9M	$21.6M	$21.2M
Accounts Payable, Current	$4.8M	$3.2M	$2.2M	$1.8M	$7.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$41.8M	-$36.1M	-$37.5M	-$48.2M	-$99.7M
Net Cash Provided by (Used in) Investing Activities	-$121.3M	$35.6M	$30.1M	-$73.4M	-$484.5K
Net Cash Provided by (Used in) Financing Activities	$166.6M	-$2.8M	-$533.6K	$60.8M	$154.9M
Payments to Acquire Property, Plant, and Equipment	$0.00	—	$13.4K	$54.2K	$484.5K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)